1194550-63-4

Basic information

• Product Name: C₄₆H₄₀Cl₂N₂O₅S
• Synonyms: C₄₆H₄₀Cl₂N₂O₅S
• CAS NO: 1194550-63-4
• Molecular Weight: 803.806
• Mol File: 1194550-63-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₄₆H₄₀Cl₂N₂O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₆H₄₀Cl₂N₂O₅S(1194550-63-4)
• EPA Substance Registry System: C₄₆H₄₀Cl₂N₂O₅S(1194550-63-4)

Safety Data

• Hazardous Substances Data: 1194550-63-4(Hazardous Substances Data)

Upstream product

• 1000210-73-0 (3,5-dichloro-benzylidene)-(2,2-diethoxy-ethyl)-amine 
• 73075-58-8 5,7-dichloro isoquinoline 
• 73075-47-5 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 1194550-56-5 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 89315-56-0 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline 
• 10203-08-4 3,5-dichlorobenzaldehyde 
• 1289646-72-5 C₂₈H₂₃Cl₂N 
• 14046-52-7 N-(2-chloroethyl)-3,5-dichlorobenzylamine hydrochloride 
• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 
• 1289646-76-9 (S)-2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propanol 
• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 

Downstream Products

• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 851785-70-1 (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 

Relevant articles and documents

PROCESSES FOR PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF

The present invention provides process for preparation of lifitegrast, amine salts of lifitegrast, process for preparation of amine salts of lifitegrast and their use in purification of lifitegrast, and also provided are process for preparation of amorphous lifitegrast and pharmaceutical compositions comprising lifitegrast prepared by the processes of the present invention.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.